Dianexin

Drug Profile

Dianexin

Alternative Names: Annexin A5 recombinant - Alavita; ASP-8597; Diannexin

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alavita Pharmaceuticals
  • Developer Astellas Pharma
  • Class Anti-inflammatories; Anti-ischaemics; Anticoagulants; Antithrombotics; Biological peptides; Calcium binding proteins; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Phosphatidylserine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Reperfusion injury

Most Recent Events

  • 01 Jul 2013 Astellas Pharma terminates phase II/III trial in Reperfusion injury in USA (NCT01442337)
  • 04 Feb 2013 Discontinued - Phase-II/III for Reperfusion injury in USA (IV)
  • 26 Oct 2012 Astellas Pharma suspends a phase II/III trial in Reperfusion injury (prevention) in USA (NCT01442337)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top